Clinuvel Pharmaceuticals Ltd (ASX: CUV) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Clinuvel Pharmaceuticals Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $800.94 million
P/E Ratio 35.59
Dividend Yield 0.15%
Shares Outstanding 49.41 million
Earnings per share 0.471
Dividend per share 0.03
Year To Date Return -38.44%
Earnings Yield 2.81%
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Clinuvel Pharmaceuticals Ltd (ASX: CUV)
Latest News

A man looks surprised as a woman whispers in his ear.
Share Market News

3 beaten up shares you might be surprised to learn are still part of the ASX 200

Here are three shares clinging precariously to their ASX 200 status...

Read more »

Smiling man sits in front of a graph on computer while using his mobile phone.
Share Market News

ASX 200 (ASX:XJO) midday update: Magellan jumps on buyback news, travel shares take off

The ASX 200 index is having a good day!

Read more »

Green arrow with green stock prices symbolising a rising share price.
Share Gainers

Why Clinuvel, Dicker Data, Healius, and Uniti shares are rising today

These ASX shares are on form on Tuesday...

Read more »

health workers shake hands and congratulate each other on good news
Healthcare Shares

Why is the Clinuvel (ASX:CUV) share price zooming 6% higher today?

Clinuvel shares are having a strong day...

Read more »

An executive in a suit smooths his hair and laughs as he looks at his laptop feeling surprised and delighted by the gains of ASX mining shares
Share Market News

Why BHP, Clinuvel, Latitude, and Peet shares are pushing higher

These ASX shares are rising today...

Read more »

a woman checks her mobile phone against the background of illuminated share market boards with graphs and tables.
Share Market News

ASX 200 (ASX:XJO) midday update: Afterpay sinks again, BHP and Rio rise

It has been a bad day for ASX investors...

Read more »

Man open mouthed looking shocked while holding betting slip
Share Fallers

These were the worst performing ASX 200 shares last week

These ASX 200 shares were out of form last week...

Read more »

man grimaces next to falling stock graph
Share Fallers

Here are 6 of the worst performing ASX shares of November

Want to know what the worst shares of November were? Look no further...

Read more »

Frequently Asked Questions

Clinuvel Pharmaceuticals listed on the ASX in 2001 and only recently declared a profit for the first time in FY2017. Since then, the company went on to achieve increased profits across both FY2018 and FY2019. It also distributed final dividends of 2 cents and 2.5 cents per share for FY2018 and FY2019 respectively. As at 17 June 2020, Clinuvel has made no announcements regarding the status of its FY2020 dividend payment.

Having only started paying dividends over the last couple of years, Clinuvel Pharmaceuticals does not currently offer a dividend reinvestment plan.

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
02 Sep 2021 $0.0250 0.00% Final 17 Sep 2021
03 Sep 2020 $0.0250 0.00% Final 18 Sep 2020
04 Sep 2019 $0.0250 0.00% Final 19 Sep 2019
21 Sep 2018 $0.0200 0.00% Final 08 Oct 2018

CUV ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Clinuvel Pharmaceuticals Ltd

Clinuvel Pharmaceuticals Limited (CUV) is a global biopharmaceutical company that develops drugs for the treatment of a range of skin disorders. The company’s flagship product is Scenesse, a drug designed for the treatment of erythropoietic protoporphyria (EPP). EPP is a rare metabolic disorder which causes burns after brief exposure to visible light, especially sunlight. It is estimated that there are 5,000 to 10,000 EPP patients worldwide. 

Clinuvel is also seeking to progress the use of Scenesse for the treatment of vitiligo, a skin disorder characterised by the appearance of white to off-white skin patches due to the loss of melanin production.

The company’s history dates back to 1987 when university researchers devised an idea of synthesising human hormones to protect the skin. Clinuvel shares have been listed on the ASX since 2001 and as a biopharmaceutical company, the Clinuvel share price can often be particularly volatile, bouncing around in response to announcements such as clinical trials and new launches.

CUV Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
16 May 2022 $16.75 $0.14 0.84% 129,859 $16.66 $16.99 $16.51
13 May 2022 $16.61 $1.97 13.46% 238,842 $14.75 $16.61 $14.75
12 May 2022 $14.64 $-0.99 -6.33% 111,877 $15.46 $15.57 $14.55
11 May 2022 $15.63 $0.00 0.00% 129,669 $15.63 $16.27 $15.01
10 May 2022 $15.63 $0.50 3.30% 164,482 $15.00 $15.84 $14.50
09 May 2022 $15.13 $-0.44 -2.83% 103,139 $15.57 $15.90 $15.11
06 May 2022 $15.57 $-0.73 -4.48% 105,826 $15.70 $15.94 $15.46
05 May 2022 $16.30 $0.54 3.43% 94,900 $16.10 $16.43 $15.91
04 May 2022 $15.76 $-0.38 -2.35% 78,501 $16.83 $16.85 $15.74
03 May 2022 $16.14 $0.25 1.57% 92,192 $15.96 $16.73 $15.96
02 May 2022 $15.89 $-0.67 -4.05% 84,746 $16.19 $16.39 $15.61
29 Apr 2022 $16.56 $0.49 3.05% 101,952 $16.20 $16.56 $15.92
28 Apr 2022 $16.07 $0.01 0.06% 96,856 $16.26 $16.61 $15.91
27 Apr 2022 $16.06 $-0.23 -1.41% 94,854 $16.07 $16.40 $15.88
26 Apr 2022 $16.29 $-0.93 -5.40% 153,384 $17.04 $17.20 $16.05
22 Apr 2022 $17.22 $-0.68 -3.80% 84,440 $17.85 $17.85 $17.13
21 Apr 2022 $17.90 $0.82 4.80% 118,153 $17.56 $18.24 $17.38
20 Apr 2022 $17.08 $-0.50 -2.84% 106,434 $17.80 $17.97 $17.08

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
10 May 2022 Philippe Wolgen Buy 1 $16,143
On-market trade.
06 May 2022 Andrew Likierman Buy 1 $9,068
On-market trade. IN GBP
22 Mar 2022 Philippe Wolgen Sell 55 $1,132,006
On-market trade.
25 Feb 2022 Jeffrey Rosenfeld Buy 485 $9,263
On-market trade.
14 Jan 2022 Brenda Shanahan Expiry 25 $628,250
As advised by the company. Lapse of conditional performance rights
30 Jun 2021 Philippe Wolgen Sell 122 $3,748,582
On-market trade.
24 Jun 2021 Brenda Shanahan Sell 25 $691,771
On-market trade.
31 May 2021 Philippe Wolgen Sell 102 $3,127,366
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Brenda Mary Shanahan Non-Executive Director Dec 2007
Mrs Shanahan has more tha 20 year's of experience in medical R&D and commercialisation. She is currently a non executive director of Phoslock Water Solutions Ltd.
Mrs Susan (Sue) Smith Non-Executive Director Sep 2019
Mrs Smith is the Chief Executive Officer of the Independent Doctors Federation, a membership organisation representing practicing physicians within the UK independent healthcare sector. Mrs Smith also manages a consultancy business, providing advisory services to a range of healthcare organisations, investors and boards of directors. Prior to her current roles Mrs Smith has a career, serving for 14 years as Chief Executive Officer of The Princess Grace Hospital, London, and 11 years as the Chief Executive Officer of The Portland Hospital for Women and Children, London. Based in London, Mrs Smith is also Non-Executive Board Chair of Women's Health (London West One) Ltd, a specialist medical practice, Non-Executive Director of Elite Medicine Ltd, a precision medicine company, and a Trustee of the HCA International Foundation.
Dr Philippe J Wolgen Chief Executive OfficerManaging Director Dec 2005
Dr Wolgen is currently leading the Group's expansion, with an immediate focus on the US and the further development of the product pipeline for various market segments. His focus has been to establish a professional management team to execute the corporate objectives set and prepare next generation of managers.
Mr Willem A Blijdorp Non-Executive DirectorNon-Executive Chairman Jan 2015
Mr Blijdorp is an internationally recongnised entrepreneur who has helped build the B&S Group, one of the largest global trading houses, in a period spanning three decades. Willem now serves on its Supervisory Board and is a majority shareholder, focussing on the Group's development and expansion strategy. Mr Blijdorp was recognised for his expertise in merger and acquisitions and commercial leadership as the Ernst & Young Entrepreneur of the Year in the Netherlands, and runner-up in its European Union awards. He is a Chair member of Remuneration and Nomination committee. He is also member of the Audit and Risk Committee.
Dr Karen Agersborg Non-Executive Director Jan 2018
Dr Agersborg had previously worked at Reading Hospital, West Reading and at Suburban Hospital, Norristown as Clinical Endocrinologist and served as Chief, Endocrinology, Diabetes, Metabolism at Chestnut Hill Hospital. Dr Agersborg had a career in managing commercial sales & distribution at Wyeth Pharmaceuticals (formerly Ayerst Laboratories). Dr Agersborg is also integral to setting US commercial strategy, pending US approval of SCENESSE, a decision on an approval expected later in 2019.
Dr Jeffrey Rosenfeld Non-Executive Director Nov 2019
Dr Rosenfeld has experience in senior healthcare and research executive roles and career in the Australian Army Reserve. He was the Founding Director of Monash University Institute of Medical Engineering (MIME-Melbourne) and acted as Board Chair for the Security and Health Executive Leadership Institute at The University of Melbourne. For 15 years Dr Rosenfeld was Director of Neurosurgery at the Alfred Hospital, concurrently holding for nine years the position of Professor and Head of the Department of Surgery at Monash University. Dr Rosenfeld is an active member of the Melbourne community and is involved in various charitable causes. He has devoted much of his time to the Australian-Aid funded Pacific Islands Project for transfer of clinical skills and knowhow to healthcare professionals in Papua New Guinea, Fiji and the Solomon Islands. One of Australia's senior and experienced military surgeons, Dr Rosenfeld served on eight deployments to Rwanda, Bougainville, East Timor, the Solomon Islands and Iraq. Having attained the rank of Major General, Dr Rosenfeld is also a former Surgeon General of the Australian Defence Force and remains active in defence and veterans' affairs organisations.In 2018, he received the International Lifetime Recognition Award of the American Association of Neurological Surgeons.
Sir Andrew Likierman Non-Executive Director Apr 2022
Sir Likierman has experience between public, private and academic positions. He is Professor of Management Practice at the London Business School and was its Dean from 2009 to 2017. He is currently working on the role of judgement in management, with his work used by many organisations. In the private sector, he served as non-executive Director of Times Newspaper Holdings Ltd, Monument Bank, Barclays Bank plc, quoted insurance Lloyds underwriter Beazley plc, Applied Intellectual Capital plc, and market research firm MORI Ltd. Among many roles in the public sector, he worked in the UK Cabinet Office, and spent 11 years as Head of the UK Government Financial Management Service, during five of which he was also the Chief Financial Officer of the UK Treasury (Finance Ministry). He was knighted for public service in 2001. He has also served as non-executive Director at the Bank of England, non-executive Chair of the (UK) National Audit Office and non-executive Director and Vice-Chairman of the Tavistock and Portman NHS Trust.
Mr Darren Keamy Chief Finance OfficerCompany Secretary Dec 2005
Darren Keamy Chief Finance OfficerCompany Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 11,368,759 30.24%
Bnp Paribas Nominees Pty Ltd Acf Clearstream 5,942,326 6.31%
BNP Paribas Nominees Pty Ltd Six Sis Ltd (Drp A/C) 5,130,894 5.99%
J P Morgan Nominees Australia Pty Limited 3,819,117 5.68%
Acn 108 768 896 Pty Ltd 2,780,040 4.08%
Ender 1 Llc 2,590,824 3.89%
Citicorp Nominees Pty Limited 2,385,285 2.79%
Dr Philippe Jacques Wolgen 975,511 2.35%
BNP Paribas Nominees Pty Ltd (Ib Au Noms Retail Client Drp) 856,796 1.79%
M Badcock And P Chu Superannuation Fund Pty Ltd 632,947 1.75%
National Nominees Limited (Db A/C) 603,990 1.75%
Dr Mark Edwin Badcock 547,563 1.60%
BNP Paribas Noms Pty Ltd (Drp) 452,391 1.58%
BNP Paribas Nominees Pty Ltd (Agency Lending Drp A/C) 271,419 1.17%
BNP Paribas Noms (Nz) Ltd (Drp) 241,539 1.14%
Merrill Lynch (Australia) Nominees Pty Limited 238,237 0.98%
Mr David William Trevorrow 222,222 0.87%
Truebell Capital Pty Ltd (Trubell Investment Fund) 200,000 0.82%
HSBC Custody Nominees (Australia) Limited A/C 2 192,758 0.82%
Mr David John Lewis 187,000 0.80%